CD19 and neoplasm: Cellular immunotherapies directed against defined lymphoma-specific antigens (anti-CD19 CAR-T treatment) or against undefined tumor antigens (allo-SCT, using the graft-versus lymphoma effect) are potentially curative in DLBCLs, even after the failure of high-dose therapy and auto-SCT.